Advanced search
Publication Cover
Expert Review of Hematology Volume 10, 2017 - Issue 10
Submit an article Journal homepage
546
Views
19
CrossRef citations to date
0
Altmetric
Drug Profile

CPX-351 in acute myeloid leukemia: can a new formulation maximize the efficacy of old compounds?

Claudia BrunettiHematology Section, Department of Emergency and Organ Transplantation, University of Bari, Bari, ItalyView further author information
,
Luisa AnelliHematology Section, Department of Emergency and Organ Transplantation, University of Bari, Bari, ItalyView further author information
,
Antonella ZagariaHematology Section, Department of Emergency and Organ Transplantation, University of Bari, Bari, ItalyView further author information
,
Giorgina SpecchiaHematology Section, Department of Emergency and Organ Transplantation, University of Bari, Bari, ItalyView further author information
&
Francesco AlbanoHematology Section, Department of Emergency and Organ Transplantation, University of Bari, Bari, ItalyCorrespondence[email protected]
ORCID Iconhttp://orcid.org/0000-0001-7926-6052View further author information
ORCID Icon
Pages 853-862 | Received 04 Apr 2017, Accepted 16 Aug 2017, Published online: 24 Aug 2017

Citations (19)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Hannah Asghari & Jeffrey Lancet. (2020) Liposomal encapsulated cytarabine and daunorubicin (CPX-351) for older patients with acute myeloid leukemia. Leukemia & Lymphoma 61:6, pages 1305-1312.
Read now
Louis S. Matza, Kristen A. Deger, Timothy A. Howell, Kimberly Koetter, Andrew M. Yeager, Donna Hogge, Vicki Fisher, Arthur C. Louie & Karen C. Chung. (2019) Health state utilities associated with treatment options for acute myeloid leukemia (AML). Journal of Medical Economics 22:6, pages 567-576.
Read now
Bingtao Zhai, Yiying Zeng, Zhaowu Zeng, Nana Zhang, Chenxi Li, Yijun Zeng, Yu You, Shuling Wang, Xiabin Chen, Xinbing Sui & Tian Xie. (2018) Drug delivery systems for elemene, its main active ingredient β-elemene, and its derivatives in cancer therapy. International Journal of Nanomedicine 13, pages 6279-6296.
Read now

Articles from other publishers (16)

Ravı KUMAR, Sunıta JHA & Akriti RAİ. (2023) Cd44 Targeted Plga Nano-Medicine For Cancer Chemotherapy- A Comprehensive Review. Journal of Immunology and Clinical Microbiology 8:3, pages 65-83.
Crossref
Leming Sun, Hongmei Liu, Yanqi Ye, Yang Lei, Rehmat Islam, Sumin Tan, Rongsheng Tong, Yang-Bao Miao & Lulu Cai. (2023) Smart nanoparticles for cancer therapy. Signal Transduction and Targeted Therapy 8:1.
Crossref
Madeleine A. Ochs, Bernard L. Marini, Anthony J. Perissinotti, Charles E. Foucar, Kristen Pettit, Patrick Burke, Dale L. Bixby & Lydia L. Benitez. (2022) Oncology stewardship in acute myeloid leukemia. Annals of Hematology 101:8, pages 1627-1644.
Crossref
Francesco Tarantini, Cosimo Cumbo, Luisa Anelli, Antonella Zagaria, Giorgina Specchia, Pellegrino Musto & Francesco Albano. (2021) Can the New and Old Drugs Exert an Immunomodulatory Effect in Acute Myeloid Leukemia?. Cancers 13:16, pages 4121.
Crossref
Soraia Fernandes, Marco Cassani, Stefania Pagliari, Petr Filipensky, Francesca Cavalieri & Giancarlo Forte. (2020) Tumor in 3D: In Vitro Complex Cellular Models to Improve Nanodrugs Cancer Therapy. Current Medicinal Chemistry 27:42, pages 7234-7255.
Crossref
Debra Wu, Anusha Pusuluri, Douglas Vogus, Vinu Krishnan, C. Wyatt ShieldsIVIV, Jayoung Kim, Amaya Razmi & Samir Mitragotri. (2020) Design principles of drug combinations for chemotherapy. Journal of Controlled Release 323, pages 36-46.
Crossref
Caspian Oliai & Gary Schiller. (2019) How to address second and therapy‐related acute myelogenous leukaemia. British Journal of Haematology 188:1, pages 116-128.
Crossref
Mohammad Norouzi, Mehrnaz Amerian, Mahshid Amerian & Fatemeh Atyabi. (2020) Clinical applications of nanomedicine in cancer therapy. Drug Discovery Today 25:1, pages 107-125.
Crossref
Anusha Pusuluri, Debra Wu & Samir Mitragotri. (2019) Immunological consequences of chemotherapy: Single drugs, combination therapies and nanoparticle-based treatments. Journal of Controlled Release 305, pages 130-154.
Crossref
Wenjie Wang & Yuk-Ching Tse-Dinh. (2019) Recent Advances in Use of Topoisomerase Inhibitors in Combination Cancer Therapy. Current Topics in Medicinal Chemistry 19:9, pages 730-740.
Crossref
Alessandra Iurlo, Daniele Cattaneo & Umberto Gianelli. (2019) Blast Transformation in Myeloproliferative Neoplasms: Risk Factors, Biological Findings, and Targeted Therapeutic Options. International Journal of Molecular Sciences 20:8, pages 1839.
Crossref
Uwe Platzbecker. (2019) Treatment of MDS. Blood 133:10, pages 1096-1107.
Crossref
Edna Cheung, Anthony J. Perissinotti, Dale L. Bixby, Patrick W. Burke, Kristen M. Pettit, Lydia L. Benitez, Julia Brown, Gianni B. Scappaticci & Bernard L. Marini. (2019) The leukemia strikes back: a review of pathogenesis and treatment of secondary AML. Annals of Hematology 98:3, pages 541-559.
Crossref
Bing Zheng, Shang-Fan Yu, Geoffrey del Rosario, Steven R. Leong, Genee Y. Lee, Rajesh Vij, Cecilia Chiu, Wei-Ching Liang, Yan Wu, Cecile Chalouni, Jack Sadowsky, Vanessa Clark, Angela Hendricks, Kirsten Achilles Poon, Wayne Chu, Thomas Pillow, Melissa M. Schutten, John Flygare & Andrew G. Polson. (2019) An Anti–CLL-1 Antibody–Drug Conjugate for the Treatment of Acute Myeloid Leukemia. Clinical Cancer Research 25:4, pages 1358-1368.
Crossref
Thomas Briot, Emilie Roger, Sylvain Thépot & Frederic Lagarce. (2018) Advances in treatment formulations for acute myeloid leukemia. Drug Discovery Today 23:12, pages 1936-1949.
Crossref
Elizabeth Anderson, Priyanka Mehta, Jonathan Heywood, Barbara Rees, Heather Bone, Gareth Robinson, Darren Reynolds, Vyv Salisbury & Lawrence Mayer. (2018) CPX-351 exhibits hENT-independent uptake and can be potentiated by fludarabine in leukaemic cells lines and primary refractory AML. Leukemia Research 74, pages 121-129.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.